International consensus: Using dermocosmetics to reduce risks of oncology treatment-related skin toxicities

B. Dreno, MD, PhD; K. Khosrotehrani, MD, PhD; G. de Barros Silva, MD; J. Ryan Wolf, PhD, MPH; D. Kerob, MD; M. Trombetta, MD; E. Alenguena, MD, MPH; P. Dielenseger, RN; M. Pan, MD, PhD; F. Scotte, MD, PhD; I. Krakowski, MD; M. Lacouture, MD;

INTRODUCTION & OBJECTIVES

Skin toxicities are one of the most frequent adverse events associated with cancer therapies. Further, new side effects emerge as new oncology drugs are approved (e.g., targeted therapies, immunotherapies) which are associated with a negative impact on quality of life, oncologic treatment dose reductions, and/or treatment discontinuation. Cancer treatment-related skin toxicities result mostly from alterations in skin barrier function, inflammation, immune reponses and phototoxicity. Maintenance of skin barrier function and photoprotection may facilitate prevention and management of adverse events to optimize treatment outcomes.